Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers-Reference-Cited by-同舟云学术

Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers

Published:2017-04-03 Issue: Volume:7 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Maughan Benjamin L.,Bailey Erin,Gill David M.,Agarwal Neeraj

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference35 articles.

1. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma;Weinstock;Ther Adv Urol,2015

2. PD-1/PD-L1 inhibitors;Sunshine;Curr Opin Pharmacol,2015

3. A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G;Carosella;Eur Urol,2015

4. Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies;Bracarda;Semin Oncol,2015

5. Immunobiology and immunotherapy in genitourinary malignancies;Tsiatas;Ann Transl Med,2016

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy;Frontiers in Immunology;2024-03-15

2. CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1–positive regulator for tumor immune evasion;Journal of Clinical Investigation;2023-12-01

3. Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study;Clinical Genitourinary Cancer;2023-10

4. Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis;International Journal of Clinical Oncology;2023-09-02

5. Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis;2023-08-16